|MDACC Study No:||2006-0697 (clinicaltrials.gov NCT No: NCT00477412)|
|Title:||Phase I/II study of bortezomib (VELCADE) plus rituximab-hyperCVAD alternating with bortezomib plus rituximab-high dose methotrexate/cytarabine in patients with untreated aggressive mantle cell lymphoma|
|Principal Investigator:||Michael Wang|
|Treatment Agent:||Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Rituximab; Vincristine|
|Study Description:||The goal of this clinical research study is to learn if bortezomib (in |
combination with rituximab plus 2 different intensive chemotherapy regimens)
can help to control the disease in patients with mantle cell lymphoma. The
safety of these drug combinations will also be studied.